DEPOSIT AGREEMENTDeposit Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of ___________, 2020, by and among (i) NANOBIOTIX S.A., a société anonyme organized and existing under the laws of the Republic of France, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...Nanobiotix S.A. • November 20th, 2020 • Pharmaceutical preparations
ContractRoyalty Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
To: Nanobiotix (the “Borrower”) 60 rue de Wattignies 75012 Paris France Attention: Finance Department and Nanobiotix Corp. (the “Guarantor”) 210 Broadway, NGIN 2nd floor, Cambridge, Massachusetts, United States Attention: Philippe Mauberna, Treasurer
Exclusive License and Collaboration AgreementLicense and Collaboration Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT IS ENTERED INTO EFFECTIVE AS OF AUGUST 06, 2012 (THE ‘‘EFFECTIVE DATE”) BETWEEN:
Amendment #1 to the Exclusive License and Collaboration AgreementThe Exclusive License and Collaboration Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • Texas
Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 European Investment Bank (the Bank) - and - Nanobiotix (the Company) Royalty Agreement Matter ref 1M0186.000509 PAARB/1864409 Hogan Lovells (Paris) LLP 17 avenue...Royalty Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations
